

Title: Increase in diagnoses associated with Post Acute Sequelae of COVID-19 (PASC) before and during the COVID-19 pandemic: a case-control study in the total population of Region Stockholm.

Running title: Associated diagnoses before and during the COVID-19 pandemic

Pia Lindberg, RN ^{1,4 *}; Gunnar Ljunggren, MD, PhD ^{2,3}; Seika Lee MD ^{2,5}; Iryna Kolosenko, PhD ¹; Michael Runold, MD, PhD ⁴; Kristina Piontkovskaya MD, PhD ^{1,4}; Caroline Wachtler, MD, PhD²; Åsa M. Wheelock, PhD^{1,4} § and Axel C. Carlsson^{2,3} §, PhD

¹ Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

²Division for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

³ Academic Primary Health Care Centre, Region Stockholm, Sweden.

⁴ Department of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Solna, Sweden.

⁵ Occupational and environmental medicine, Medical Sciences, Uppsala University, Uppsala, Sweden.

§ Contributed equally

*Corresponding author:

Pia Lindberg, Respiratory Medicine Unit, Dept. of Medicine Solna and center for Molecular Medicine, Karolinska Institutet, Solnavägen 30, Bioclinicum Lungforskningslab, J7:30, 17174 Solna, Sweden.
Pia.lindberg@ki.se +46 702 645 854

Tables: 1-2

Supplemental Digital Content files: 1 (.docx)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Objectives:

Post Acute Sequela of COVID-19 (PASC) is a remaining health concern after the pandemic. We aimed to investigate the prevalence of diagnoses and symptom diagnoses-recorded before and during the pandemic in individuals who later received PASC.

Methods:

A case-control study was designed to investigate the prevalence of registered diagnoses in adult, non-hospitalized PASC patients (cases) 2019, 12 months before and 6 months after the PASC diagnosis compared to matched controls. Data was extracted from the Stockholm Region's data warehouse (VAL).

Results:

Results indicate higher diagnosis rates for men and women with PASC already in 2019 and 12 months before diagnosis; slightly decreasing 6 months after PASC. Cases showed more pre-pandemic respiratory diagnoses compared to controls. In 2019, cases had higher rates of acute upper respiratory tract infection (OR 2.47 for men, 2.22 for women), asthma (OR 1.76 (men), 1.95 (women)), and bronchitis (OR 2.15 (men), 2.71 (women)) than controls.

Conclusions:

The present study showed that individuals who later developed PASC were more likely than others to show respiratory symptoms before COVID-19. Pre-existing vulnerabilities observed before the pandemic in those later diagnosed with PASC in 2021 suggest a potential link between prior conditions and PASC development.

Keywords

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC); Case Control Studies; Signs and Symptoms, Respiratory; Cardiovascular Disorders; Somatic Symptoms; Symptom Cluster; Neurobehavioral Signs and Symptoms; Primary Healthcare; Diagnosis

List of abbreviations

PASC - Post Acute Sequelae of COVID-19, VAL - Stockholm Regional Health Care Data Warehouse; ICD-10 - International Classification of Diseases, 10th edition; OR - odds ratio; CI - confidence interval.

INTRODUCTION

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) is a new condition specific to SARS-Cov-2 infection with a spectrum of diverse persistent symptoms involving multiple organ systems. PASC – sometimes referred to as “long covid” - is defined through the persistent symptoms such as post-exertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire and capacity, loss of change in smell or taste, thirst, chronic cough, chest pain and abnormal movements 6 months after the infection. In autumn 2020, WHO introduced a definition and a diagnostic code for Post-Acute COVID. In 2021 Delphi consensus provided the guidelines for diagnosis of Post-Acute COVID (1, 2). This consensus specifies that symptoms of the syndrome can be diverse and persist for at least three months, can fluctuate in intensity over time and cannot be attributed to any other diagnosis. Different centers use different nomenclature for the syndrome (3-7). In this study, we will use the term PASC.

The complexity and unknowns surrounding PASC's nature, risk factors, and diagnosis distribution highlight the urgent need for comprehensive studies to distinguish it from other post-infectious states and better understand its impact on the general population. Understanding whether PASC represents a unified condition or a group of different phenotypes remains unclear, as its pathophysiology is yet unknown. PASC may be related to persistent viral reservoirs, autoimmunity, or direct organ injury, and currently, no molecular biomarkers are available for its diagnosis (8). Pathophysiological processing to determine PASC phenotypes through biological samples is crucial for understanding organ involvement. Similarity between PASC and post-intensive care syndrome (PICS) symptoms, and the higher prevalence of PASC in individuals who received intensive care for acute infection initially led to the theory that these symptoms were an aftermath of such care (9). However, studies indicate a wide variation in prevalence. Some studies show a prevalence around 10% among non-hospitalized patients with mild infections who also experience PASC, suggesting a distinct mechanism (3, 5). Longitudinal studies suggest that up to 46% of patients after a non-severe infection have persistent symptoms 12 months after COVID-19 (10, 11). Davies et al. argue that the prevalence among non-hospitalized patients is 10-30% (7). Many PASC symptoms are also common in the broader population, independent of previous infection. Therefore, a key challenge lies in distinguishing symptoms specific to PASC.

We aimed to investigate the prevalence of symptoms frequently associated with PASC prior to the COVID-19 pandemic (2019), 12 months prior to receiving PASC diagnosis and 6 months after the diagnosis in Stockholm County in patients with PASC and in matched controls.

METHODS

VAL-warehouse

The Stockholm County Healthcare Region provides healthcare services under the governance of the Stockholm Region. With over 2.2 million residents, the Stockholm Region plays a crucial role in Sweden, covering a variety of urban and rural areas, within which the Stockholm County Healthcare Region delivers health and medical care. Primarily funded through taxes, healthcare services are meticulously documented in the Stockholm Regional Health Care Data Warehouse (VAL). VAL's credibility is evidenced by its contribution to national health registers and benchmarking reports (12). Since 1997, diagnoses have been systematically coded according to the World Health Organization's International Classification of Diseases, 10th revision (ICD-10), ensuring standardization and consistency in healthcare data management (13). We have access to all diagnoses, visits and all care forms in the Region, both primary care and specialist visits.

Study Population

The study cohort comprised adults aged 18 and older residing in the Stockholm Region for the entire duration of the study, spanning from January 2019 to February 2022. Individuals who relocated in or out of the region, or died during this period, were excluded. Inclusion criteria for PASC (cases) included: a post-COVID-19 diagnosis, U09.9 (ICD-10), in individuals who were not hospitalized (non-hospitalized) for their acute phase of COVID-19. The PASC diagnosis could be obtained for the first time between January 1 to December 31 2021 in primary or specialized healthcare settings.

Each case was matched with 10 controls based on age, sex and neighborhood socioeconomic status at data collection. Based on the date when cases got their PASC diagnosis and controls were identified, diagnostic codes related to post-COVID symptoms were extracted (3,4). We extracted diagnoses recorded during the year 2019, as well as 12 months prior to and up to 6 months (a minimum of 40 days) after the date of the U09.9 diagnosis for both cases and for matched controls during the same time frame. The reason for extracting diagnoses 6 months after instead of 12 months was that we only had access to data from the registry until February 10, 2022. The study design is illustrated in Figure 1.

Diagnoses

ICD-10 diagnoses utilized in this study are presented in Supplementary Table 1 (13). The diagnosis code for PASC is U09.9, post COVID-19. The respiratory symptom diagnoses are: Acute upper respiratory tract infection (J06.9), Acute bronchitis (J20.9, J40.9), Asthma (J45.1, J45.8, J45.9, J46.9) and symptoms diagnoses are Cough (R05), Dyspnea (R06.0) and Other and unspecified respiratory disorders (R06.8). Cardiac-related diagnoses and diagnoses, including cardiac symptom diagnoses were Palpitation (R00.2), Chest pain, unspecified (R07.4) and Other Specified Cardiac Arrhythmias (POTS, I49.8). Other PASC symptoms were Headache (R51.9), Fatigue syndrome after viral infection (G93.3), Depression (F32) and Anxiety (F41) (13). In addition to these symptom-related diagnoses, diagnostic codes COVID-19, virus identified (U07.1) and COVID-19, virus not identified (U07.2) were also included in the analysis.

Neighborhood socioeconomic status

To categorize various municipalities and regions within the area based on socio-economic status, the Mosaic tool, developed by the marketing company Experian, was employed. Originally designed to optimize sales efficiency, Mosaic has demonstrated credibility in epidemiological studies due to its ability to generate multivariable models, encompassing over 400 variables. Through the utilization of Mosaic, distinct levels of socioeconomic status—high, medium, and low—were delineated (14, 15).

Ethics

Ethical approval was obtained from the Swedish Ethical Review Authority (2021-01016) with later amendments (2021-05735-02).

Statistical methods

Conditional logistic regression was used to calculate odds ratios (OR) with 99% confidence intervals (CI) for the risk for occurrence of defined diagnoses in cases versus controls. Statistical analysis and data management were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC).

RESULTS

We identified a total of 5589 individuals with the diagnostic code U09.9 who met our inclusion criteria. These individuals were matched with a total of 47561 controls. Among the 5589 cases, 3862 (69,1%) were woman and 1727 (30,9%) were men. The mean and median age were 47-48 years old (18 to 90 years old), more details presented in Supplementary Table 2- 4.

Twelve months prior to receiving the PASC diagnosis, 48% of cases and 86% controls did not have any of the diagnoses that were investigated, whereas 29% of cases and 11% of controls had 1 registered diagnosis, 14% of cases and 2% of controls had 2 diagnoses (Figure 2, Supplementary Table 5). Six months after the PASC diagnosis, 70% of cases and 92% of controls had no registered diagnoses, which constitutes an increase in people without any diagnoses compared to the period prior to PASC (Supplementary table 6).

There was a higher prevalence of all studied diagnoses for cases in comparison to their matched controls both prior to and after the COVID-19 pandemic (Figure 3). Diagnoses with the statistically highest significant odds ratio before the pandemic (2019) were Acute upper respiratory tract infection (J06.9), Acute Bronchitis (J20.9, J40.9) and Headache (R51.9) for men, and Other Specified Cardiac Arrhythmias (POTS, I49.8), Headache (R51.9) and Acute upper respiratory tract infection J06.9 for women (Figure 3A, 3B). Additionally, diagnoses with the highest significant odds ratio 12 month before PASC were Other Specified Cardiac Arrhythmias (POTS, I49.8), Fatigue syndrome after viral infection (G93.3) and Dyspnea (R06.0) in men and Fatigue syndrome after viral infection (G93.3), Other Specified Cardiac Arrhythmias (POTS, I49.89), and Other and unspecified respiratory disorders (R06.8) in women.

The diagnoses with the highest significant odds ratio 6 month after PASC were Fatigue syndrome after viral infection (G93.3), Palpitation (R00.2) and Other and unspecified respiratory disorders (R06.8) in men and Other Specified Cardiac Arrhythmias (POTS, I49.8), Fatigue syndrome after viral infection (G93.3) and Dyspnea (R06.0) in women (Figure 3C, 3D, tabl 1-2).

The association between PASC and relevant symptom diagnoses is shown as odds ratio 12 months before and 6 months after the PASC diagnosis in Table 1 for women, and in Table 2 for men. As demonstrated, for Asthma (J45), the odds ratio was 1.95 for women and 1.76 for men in 2019, 3.76 for women and 4.18 for men 12 months before PASC diagnosis and 3.69 for women and 4.49 for men 6 months after the PASC diagnosis.

Women in the PASC group had an odds ratio above 1.5 for all 13 investigated diagnoses in 2019, while men had 10 diagnoses with an odds ratio above 1.5. Most of the diagnoses exhibited a statistically significantly higher odds ratio, both among women and men 12 months prior to

the PASC diagnosis. Six months after the PASC diagnosis the odds ratios were in general lower than prior to diagnosis (Table 1-2).

DISCUSSION

Main findings

The results indicate that patients with PASC to a greater extent than their controls had been diagnosed with respiratory diagnoses as well as chest pain and anxiety before the pandemic, with a minor sex difference. In 2019, more patients with PASC than controls had acute upper respiratory tract infection, asthma, bronchitis and chest pain. The frequencies of all diagnoses were higher in both men and women with PASC 12 months prior to PASC diagnosis, followed by somewhat lower rates of most diagnoses 6 months after the PASC diagnosis. .

Comparisons with other studies

Our study corroborates previous findings that PASC is more prevalent among women and is significantly associated with pre-existing conditions like asthma. We identified 5589 cases of PASC, with 69.10% being women, aligning with existing literature on the higher prevalence of PASC among women, both in hospitalized and non-hospitalized patients (16-19). Furthermore, our study highlights that individuals with PASC had a higher prevalence of various comorbidities compared to their matched controls, even prior to the COVID-19 pandemic and their primary SARS-CoV-2 infection. We found significantly higher odds of Asthma among PASC cases compared to controls, both before and after the PASC diagnosis. Female sex and asthma are supported by a study that has coordinated analyses of survey data and electronic records from the UK (16). That suggests that sex and pre-existing health conditions may predispose to the development of PASC, and that individuals with such diagnoses are more likely to be diagnosed with PASC (16). A population-based cohort study carried out in the Stockholm Region, similar to our research, indicated that females were more likely to receive a PASC diagnosis. Moreover, comorbid conditions, especially mental health issues and asthma, as well as a history of healthcare usage, were more strongly associated with PASC in non-hospitalized individuals than in those who had been hospitalized (19). A recently published nationwide observational study utilizing Swedish registries with matched controls also identifies the female sex as a risk of receiving a diagnosis of PASC. The study selected all individuals with a positive COVID-19 diagnosis between February 2020 and May 2021, subsequently examining additional diagnoses. However, nationwide access to primary care data was not available, and various healthcare registries were followed instead.

Besides the female sex, the most common symptoms and diagnostic codes (ICD-10 R-chapter (13)) for healthcare visits associated with PASC were dyspnea, malaise/fatigue, abnormal findings on pulmonary diagnostic imaging, and chest pain (20). Similarities exist with findings from this study focusing on primary care data, particularly regarding abnormal findings on pulmonary diagnostic imaging.

Our study reveals a strong association between PASC and diagnoses such as asthma and depression, both before and after the PASC diagnosis. We found higher odds of asthma and depression among PASC cases compared to controls, both before and after the PASC diagnosis. A longitudinal cohort study, also conducted within Region Stockholm, Sweden, and utilizing the VAL database, showed that depression was associated with a higher risk of PASC, OR of 1.78 (CI 1.54-2.05) for women and 1.92 (CI 1.52-2.43) for men (18). The findings in this study are supported by other studies (6, 16, 18). Furthermore, the results in the present study regarding symptoms are supported by data from surveys answered by non-hospitalized individuals with PASC, which included questions regarding self-reported symptoms. The results in the present study regarding symptoms are in line with data from surveys using self-reported symptoms in non-hospitalized individuals with PASC, with similar affected age groups and more women than men with PASC (6, 16, 18).

The 5589 cases identified in this case-control study based on inclusion/exclusion criteria are low compared to international estimates of a PASC-prevalence of approximately 10% (3, 5, 7).

Potential explanations for our findings

Underreporting of PASC and diagnostic challenges likely contribute to a significant number of undiagnosed cases among controls. Hence, there appears to be an underreporting of PASC, with potentially one in ten controls remaining undiagnosed as PASC cases. Initially, numerous clinicians engaged in debate regarding the classification of PASC as a syndrome, a discourse that might have adversely affected the diagnostic process for PASC. Looking at the number of diagnoses (of those investigated) 12 months (86.48%) before and 6 months (92.18%) after the PASC diagnosis for the controls, the controls have not sought care for these diagnoses to a high extent. This would then suggest a healthy population or a population not seeking care. Or a population without care to seek - for a long time there were no clinicians to refer these patients to. Additionally, controls may have lingering symptoms, but they may not be severe enough or affect their quality of life and well-being enough to make them seek care. Also, the relatively low

prevalence of PASC in this study may be due to the lack of solid clinical criteria for diagnosing the condition and that the diagnosis is based on exclusion criteria.

Strengths and limitations

The large, population-based cohort and comprehensive healthcare data in our study offer significant strengths, but several limitations must be addressed. Additionally, the matching of cases and controls based on age and sex minimizes potential confounding bias. However, our study has limitations that warrant consideration. We used a retrospective study design, yet all diagnoses were registered prospectively in the register we used, limiting information bias regarding the ascertainment of diagnoses.

During the COVID-19 pandemic, healthcare systems worldwide underwent significant changes and adaptations, affecting guidelines, clinical procedures, and patient interactions. These alterations potentially impacted medical investigations, diagnostic procedures, and treatments, leading to delays or undiagnosed conditions. The absence of physical visits with primary care physicians may have contributed to these delays, as evidenced by the reluctance to register certain symptoms or diagnoses, such as Fatigue syndrome after viral infection. This discomfort with new diagnoses might also extend to other registered symptom diagnoses six months later, where primary care settings may have become more accustomed to registering symptoms. However, it is important to note that this study is based on electronic health records, which may not fully capture a patient's overall health but rather focus on reasons for healthcare visits.

Clinical implications

Understanding the significance of pre-existing health conditions is crucial in assessing the risk and prognosis of PASC. By identifying individuals at higher risk of developing PASC-related complications can inform targeted interventions and support strategies to mitigate adverse outcomes. Examining the temporal patterns of diagnoses among PASC cases revealed interesting trends. While most cases and controls did not have registered diagnoses 12 months before the PASC diagnoses, the number of cases with registered diagnoses was lower 6 months after the PASC diagnoses. This implies a possible decrease in healthcare-seeking behavior or health enhancement among patients with PASC. In a sense, this article demonstrates the utility of identifying "new" symptom diagnoses, while also highlighting their potential risks.

Our study highlights etiology and key clinical implications for the diagnosing of PASC and finding risk factors in non-hospitalized individuals. We found a higher prevalence of comorbidities in individuals with PASC compared to controls, suggesting that certain pre-existing conditions may be predisposing to PASC (3, 4, 7). Future research incorporating longitudinal data and objective measures of PASC-related symptoms is needed to validate our findings and provide further insights into the epidemiology and clinical course of PASC.

Conclusions

This study contributes to the growing body of literature on PASC by providing insights into its etiology, prevalence, temporal patterns, and association with pre-existing and co-existing diagnoses. More men and women with PASC than in controls had received a diagnosis of asthma, bronchitis and chest pain in 2019. The rates of all diagnoses were higher in men and women with PASC 12 months prior to diagnosis, followed by somewhat lower rates of diagnoses 6 months after the PASC diagnosis. By identifying symptoms in individuals with PASC before the diagnoses, we can begin characterizing risk factors for non-hospitalized individuals to develop PASC after COVID- 19 infection. A higher frequency was seen for all the examined diagnoses in the study among those who developed PASC compared to their controls.

Conflicts of Interest

None of the authors report any conflicts of interest.

Funding

Funding was received from Region Stockholm FoUI-97300 (ACC), Swedish Heart-lung foundation (ÅMW), and Swedish Research Council (ÅMW).

Author contributions

Study concepts: PL, ACC, GL, SL, ÅWM

Data acquisition: ACC

Quality control of data and algorithms: GL and ACC

Data analysis and interpretation: all authors

Statistical analysis: GL, PL

Manuscript preparation: PL, ACC

Manuscript editing: all authors

Manuscript review: all authors

References

1. National Institute for Health and Care Excellence: Clinical Guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE)
- Copyright © NICE 2020.; 2020.
2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis.* 2022;22(4):e102-e7.
3. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *Bmj.* 2021;374:n1648.
4. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021;27(4):601-15.
5. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *Jama.* 2021;325(19):2015-6.
6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Author Correction: Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol.* 2023;21(6):408.
7. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol.* 2023;21(3):133-46.
8. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *Jama.* 2023;329(22):1934-46.
9. Vrettou CS, Mantziou V, Vassiliou AG, Orfanos SE, Kotanidou A, Dimopoulou I. Post-Intensive Care Syndrome in Survivors from Critical Illness including COVID-19 Patients: A Narrative Review. *Life (Basel).* 2022;12(1).
10. Augustin M, Stecher M, Wüstenberg H, Di Cristanziano V, Sandaradura de Silva U, Picard LK, et al. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study. *Front Immunol.* 2023;14:1226622.
11. Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, et al. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. *Clin Infect Dis.* 2023;76(3):e60-e70.
12. Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. *BMC Public Health.* 2013;13:670.
13. Organization WH. International Statistical Classification of Diseases and Related Health Problems (ICD) [Internet]. World Health Organization; [Available from: <https://www.who.int/standards/classifications/classification-of-diseases>.
14. Douglas L, Szatkowski L. Socioeconomic variations in access to smoking cessation interventions in UK primary care: insights using the Mosaic classification in a large dataset of primary care records. *BMC Public Health.* 2013;13:546.
15. Sharma A, Lewis S, Szatkowski L. Insights into social disparities in smoking prevalence using Mosaic, a novel measure of socioeconomic status: an analysis using a large primary care dataset. *BMC Public Health.* 2010;10:755.

16. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. *Lancet Digit Health*. 2022;4(7):e532-e41.
17. Wallensten J, Ljunggren G, Nager A, Wachtler C, Petrovic P, Carlsson AC. Differences in psychiatric comorbidity patterns in patients diagnosed with chronic stress-induced exhaustion disorder and depression - A cohort study in the total population of Region Stockholm. *J Affect Disord*. 2024;351:765-73.
18. Kisiel MA, Lee S, Malmquist S, Rykatkin O, Holgert S, Janols H, et al. Clustering Analysis Identified Three Long COVID Phenotypes and Their Association with General Health Status and Working Ability. *J Clin Med*. 2023;12(11).
19. Hedberg P, Granath F, Bruchfeld J, Askling J, Sjöholm D, Fored M, et al. Post COVID-19 condition diagnosis: A population-based cohort study of occurrence, associated factors, and healthcare use by severity of acute infection. *J Intern Med*. 2023;293(2):246-58.
20. Hanna MO, Osvaldo F-R, Ida Henriette C, Sebastian K, Johan N, Lill T, et al. How do clinicians use post-COVID syndrome diagnosis? Analysis of clinical features in a Swedish COVID-19 cohort with 18 monthsâ€™ follow-up: a national observational cohort and matched cohort study. *BMJ Public Health*. 2024;2(1):e000336.

Figures




Figure 1. Study design of cases and controls and the different study periods.




Figure 2. Number of recorded diagnoses for cases and controls 12 months before and 6 months after PASC diagnosis.




Figure 3. Summary of the effects of investigated diagnoses on PASC development.

The odds ratios (OR) and 99% CI are presented for females and males respectively in 2019 (A, B), 12 months prior to PASC diagnosis (C, D) and 6 months after PASC diagnosis (E, F). OR for POTS not included in this figure for better visibility.




Figure 4. Comparison of diagnosis frequencies between PASC patients and healthy controls. The frequencies of the indicated diagnoses were extracted for PASC patients (cases) and their matched healthy controls for three time points: 2019 (A, B for females and males respectively), 12 months prior to PASC diagnosis (C, D for females and males respectively) and 6 months after PASC diagnosis (E, F for females and males respectively).

TABLES

Table 1. The association between PASC and other diagnoses in women shown as odds ratios in the year 2019, 12 months before the PASC diagnosis, and 6 months after the PASC diagnosis.

	Female	Female	Female
Diagnoses	2019 Odds ratios (99% CI)	12 months before Odds ratios (99% CI)	6 months after Odds ratios (99% CI)
Depression F32	1.57 (1.26-1.97)	1.92 (1.51- 2.46)	2.19 (1.60-2.30)
Anxiety F41	1.65 (1.41-1.93)	2.50 (2.16- 2.89)	2.65 (2.22-3.17)
Fatigue syndrome after viral infection G93.3	1.96 (0.86-4.48)	37.86 (27.16-52.77)	31.27 (21.34-45.82)
Acute upper respiratory tract infection J06.9	2.22 (1.93-2.56)	5.87 (4.89-7.05)	3.15 (2.23-4.43)
Acute bronchitis J20.9, J40.9	2.15 (1.60-2.90)	5.48 (3.60-8.33)	2.33 (1.15-4.72)
Asthma J45.1, J45.8, J45.9, J46.9	1.95 (1.58-2.41)	3.76 (3.13-4.51)	3.69 (2.91-4.68)
Palpitation R00.2	2.01 (1.52-2.66)	6.92 (5.73-8.37)	6.97 (5.42-8.97)
Cough R05	1.78 (1.43-2.21)	6.06 (5.02-7.31)	3.16 (2.35-4.26)
Dyspnea R06.0	1.94 (1.35-2.80)	14.87 (12.54-17.64)	11.73 (9.14-15.03)
Other and unspecified respiratory disorders R06.8	3.34 (0.96-11.57)	18.77 (7.94-44.41)	9.80 (2.34-41.11)
Chest pain R07.4	2.02 (1.57-2.60)	6.21 (5.22-7.39)	3.23 (2.46-4.24)
Headache R51.9	2.45 (1.96- 3.05)	4.67 (3.90-5.59)	5.29 (4.13-6.78)
Other Specified Cardiac Arrhythmias (POTS) I49.8	6.27 (1.88-44.83)	28.35 (11.17-71.96)	85.50 (28.31-258.21)

Table 2. The association between PASC and relevant diagnoses in men shown as OR and 99% CI in the year 2019, 12 months before the PASC diagnosis, and 6 months after the PASC diagnosis.

	Male	Male	Male
Diagnoses	2019 Odds ratios (99% CI)	12 months before Odds ratios (99% CI)	6 months after Odds ratios (99% CI)
Depression F32	1.40 (0.88-2.23)	2.79 (1.80-4.30)	4.15 (2.53-6.81)
Anxiety F41	2.10 (1.56-2.84)	3.33 (2.55-4.34)	3.41 (2.46-4.72)
Fatigue syndrome after viral infection G93.3	2.22 (0.29-17)	42.56 (23.11-78.40)	81.41 (29.06-228.10)
Acute upper respiratory tract infection J06.9	2.47 (1.89-3.23)	6.60 (4.71-9.27)	4.22 (2.36-7.56)
Acute bronchitis J20.9, J40.9	2.71 (1.62-4.54)	7.86 (4.02-15.37)	2.48 (0.67-9.12)
Asthma J45.1, J45.8, J45.9, J46.9	1.76 (1.19-2.58)	4.18 (3.07-5.70)	4.49 (2.99-6.73)
Palpitation R00.2	1.93 (0.99-3.78)	7.53 (5.04-11.23)	9.80 (5.51-17.44)
Cough R05	1.64 (1.12-2.42)	7.90 (5.92-10.55)	4.62 (2.93-7.31)
Dyspnea R06.0	1.89 (0.98-3.65)	15.62 (11.91-20.50)	12.86 (8.60-19.25)

Other and unspecified respiratory disorders R06.8	0	3.34 (0.74-15.08)	9 (1.45-55-70)
Chest pain R07.4	2.41 (1.71-3.40)	5.98 (4.62-7.74)	4.27 (2.86-638)
Headache R51.9	2.89 (1.86-4.50)	6.35 (4.48-9.00)	4.94 (3.14-7.77)
Other Specified Cardiac Arrhythmias (POTS) I49.8	0	63.37 (4.03-995.91)	0

Supplementary Tables

Supplementary Table 1. ICD-10 diagnoses extracted from VAL database in this study (13)

F32	Depression
F41	Anxiety
G93.3	Fatigue syndrome after viral infection
J06.9	Acute upper respiratory tract infection
J20.9	Acute bronchitis
J40.9	Bronchitis unspecified as acute or chronic
J45.1	Non-allergic asthma
J45.8	Mixed asthma
J45.9	Asthma
J46.9	Acute severe asthma
R00.2	Palpitation
R05	Cough
R06.0	Dyspnoea
R06.8	Other and unspecified respiratory disorders
R07.4	Chest pain, unspecified
R51.9	Headache
U07.1	Covid-19, virus identified
U07.2	Covid-19, virus non- identified
U09.9	Post-infectious condition after Covid-19, unspecified
I49.8	Other Specified Cardiac Arrhythmias (POTS)
U08.9	Covid-19 in own medical history, unspecified

Supplementary Table 2. Mean age, median age, and the number of cases and controls based on sex.

Gender	Group	N	Median, years
Female	Case	3862	47
Male	Case	1727	48
Female	Control	32 151	47
Male	Control	15 410	47

Supplementary Table 3. The frequency of all studied diagnoses in the year 2019, 12 months before, and 6 months after the PASC diagnosis.

	Female 2019		Female 12 month before the diagnosis		Female 6 month after the diagnosis	
Diagnoses	Frequency for Cases n=3862 (%)	Frequency for controls n=32151 (%)	Frequency for cases n=3862 (%)	Frequency for controls n=32151 (%)	Frequency for cases n=3862 (%)	Frequency for controls n=32151 (%)
Depression F32	162 (4.19%)	870 (2.71%)	140 (3.63%)	617 (1.92%)	87 (2.25%)	335 (1.04%)
Anxiety F41	357 (9.24%)	1873 (5.83%)	445 (11.52%)	1599 (4.97%)	287 (7.43%)	948 (2.95%)
Fatigue syndrome after viral infection G93.3	12 (0.31%)	51 (0.16%)	318 (8.23%)	76 (0.24%)	210 (5.44%)	59 (0.18%)
Acute upper respiratory tract infection J06.9	461 (11.94%)	1852 (5.6%)	349 (9.04%)	535 (1.66%)	79 (2.05%)	212 (0.66%)
Acute bronchitis J20.9, J40.9	96 (2.49%)	376 (1.17%)	63 (1.63%)	97 (0.3%)	17 (0.44%)	61 (0.19%)
Asthma J45.1, J45.8, J45.9, J46.9	193 (5%)	845 (2.63%)	306 (7.92%)	722 (2.25%)	174 (4.51%)	407 (1.27%)
Palpitation R00.2	108 (2.80%)	454 (1.41%)	345 (8.93%)	449 (1.4%)	194 (5.02%)	242 (0.75%)
Cough R05	178 (4.61%)	849 (2.964%)	334 (8.65%)	497 (1.55%)	106 (2.74%)	284 (0.88%)
Dyspnea R06.0	62 (1.61%)	268 (0.83%)	621 (16.08%)	409 (1.27%)	258 (6.68%)	195 (0.61%)
Other and unspecified respiratory disorders R06.8	6 (0.16%)	15 (0.05%)	29 (0.75%)	13 (0.04%)	7 (0.18%)	6 (0.02%)
Chest pain R07.4	135 (3.5%)	566 (1.76%)	400 (10.36%)	588 (1.83%)	127 (3.29%)	335 (1.04%)
Headache R51.9	184 (4.76%)	645 (2.01%)	334 (8.65%)	641 (1.99%)	180 (4.66%)	295 (0.92%)
Other Specified Cardiac Arrhythmias (POTS) I49.8	3 (0.08%)	4(0.01%)	33 (0.85%)	10 (0.03%)	59 (1.53%)	6 (0.02%)
Covid-19, virus identified U07.1	X	X	900 (23.3%)	342 (1.06%)	139 (3.6%)	175 (0.54%)

Covid-19, virus non- identified U07.2	X	X	463 (11.99%)	297 (0.92%)	51 (1.32%)	34 (0.11%)
Covid-19 in own medical history, unspecified U08.9	X	X	312 (8.08%)	73 (0.23%)	279 (7.22%)	83 (0.26%)

Supplementary Table 4. The frequency of all studied diagnoses in the year 2019, 12 months before, and 6 months after the PASC diagnosis.

	Male 2019		Male 12 month before diagnosis		Male 6 month after diagnosis	
Diagnoses	Frequency for Cases n=1727 (%)	Frequency for Controls n=15410 (%)	Frequency for cases n=1727 (%)	Frequency for controls n=15410 (%)	Frequency for cases n=1727 (%)	Frequency for controls n=15410 (%)
Depression F32	36 (2.08%)	231 (1.50%)	47 (2.72%)	154 (1%)	40 (2.32%)	88 (0.57%)
Anxiety F41	97 (5.62%)	427 (2.77%)	136 (7.87%)	387 (2.51%)	89 (5.15%)	243 (1.58%)
Fatigue syndrome after viral infection G93.3	2 (0.12%)	8 (0.05%)	99 (5.73%)	22 (0.14%)	61 (3.53%)	7 (0.05%)
Acute upper respiratory tract infection J06.9	126 (7.30%)	474 (3.08%)	103 (5.96%)	146 (0.95%)	29 (1.68%)	62 (0.40%)
Acute bronchitis J20.9, J40.9	33 (1.91%)	109 (0.71%)	28 (1.62%)	32 (0.21%)	5 (0.29%)	18 (0.12%)
Asthma J45.1, J45.8, J45.9, J46.9	55 (3.18%)	281 (1.82%)	105 (6.08%)	234 (1.52%)	62 (3.59%)	126 (0.82%)
Palpitation R00.2	18 (1.04%)	83 (0.54%)	77 (4.46%)	95 (0.62%)	42 (2.43%)	39 (0.25%)
Cough R05	54 (3.36%)	294 (1.91%)	154 (8.92%)	189 (1.23%)	49 (2.84%)	96 (0.62%)
Dyspnea R06.0	19 (1.10%)	89 (0.58%)	244 (14.13%)	161 (1.04%)	100 (5.79%)	73 (0.47%)
Other and unspecified respiratory disorders R06.8	0 (0%)	4 (0.03%)	4 (0.23%)	11 (0.07%)	4 (0.23%)	4 (0.03%)
Chest pain R07.4	74 (4.28%)	279 (1.81)	173 (10.02%)	281 (1.82%)	62 (3.59%)	133 (0.86%)
Headache R51.9	46 (2.66%)	144 (0.93%)	95 (5.50%)	140 (0.91%)	51 (2.95%)	94 (0.61%)
Other Specified Cardiac Arrhythmias (POTS) I49.8	0 (0%)	3 (1.02%)	7 (0.41%)	1 (0.01%)	12 (0.69%)	0 (.0%)
Covid-19, virus identified U07.1	X	X	336 (19.46%)	173 (1.12%)	50 (2.90%)	86 (0.56%)
Covid-19, virus non- identified U07.2	X	X	167 (9.67%)	100 (0.65%)	13 (0.75%)	18 (0.12%)
Covid-19 in own medical history, unspecified U08.9	X	X	144 (8.34%)	24 (0.16%)	108 (6.25%)	37 (0.24%)

Supplementary Table 5. Number of symptoms/ diagnoses–12 months prior to the PASC diagnosis.

Number of diagnoses	Case	Control	Total
0	2685 48.04%	41 130 86.48%	43 815
1	1611 28.82%	5091 10.70%	6702
2	781 13.97%	1079 2.27%	1860
3	324 5.80%	204 0.43%	528
4	125 2.24%	46 0.10%	171
5	42 0.75%	7 0.01%	49
6	14 0.25%	2 0.00%	16
7	6 0.11%	2 0.00%	8
8	1 0.02%	0 0.00%	1
Total	5589	47 561	53 150

Supplementary Table 6. Number of symptoms/ diagnoses-6 months after the PASC diagnosis.

Number of diagnoses	Case	Control	Total
0	3899 69.76%	43 841 92.18%	47 740
1	1166 20.86%	3163 6.65%	4329
2	392 7.01%	473 0.99%	865
3	94 1.68%	78 0.16%	172
4	31 0.55%	5 0.01%	36
5	6 0.11%	1 0.00%	7
6	1 0.02%	0 0.00%	1
Total	5589	47 561	53 150